Dr. Wayne W. Bixenman, MD

Dr. Bixenman practices at Sean J. McCafferty, MD in Tucson, Arizona.

Dr. Bixenman's NPI, 1790862522, was assigned on November 1, 2006. Dr. Bixenman holds Arizona license 11672.

Dr. Bixenman's primary practice is Sean J. McCafferty, MD, at 6422 E Speedway Blvd, Tucson, AZ 85710 in Pima County. The practice phone is (520) 327-3487.

Dr. Bixenman's primary practice is Sean J. McCafferty, MD in Tucson, Arizona. Dmand AI also links Dr. Bixenman to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bixenman practices. Vendor and product names are available with a free account.

Neuro-ophthalmology is Dr. Bixenman's primary specialty in the NPI Registry, under taxonomy code 207WX0109X. Dr. Bixenman is licensed in Arizona.

CMS data shows 1,894 Medicare services from Dr. Bixenman across 10 procedure codes in 2024, for 476 Medicare patients. Medicare paid $106,216 for them. Every service was in an office.

CMS counts 476 Medicare patients who saw Dr. Bixenman in 2024. The largest group is 65 to 74, with 206 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 3% are also on Medicaid. Their average risk score is 1.25, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Bixenman's median patient age at 68, with 65% women.

In 2024, Dr. Bixenman wrote 112 Medicare Part D claims for 42 patients. 63% of them were for generic drugs. CMS names the drug for 70 of them, across 4 drugs with 11 or more claims each, at $1,865 in total drug cost. In 2023, CMS named 52 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bixenman for performance year 2024, reported as part of a group. Dr. Bixenman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 12 procedures of cataract surgery by Dr. Bixenman, more than 34% of the clinicians it reports for that procedure.

CMS Open Payments shows 39 general payments to Dr. Bixenman from 6 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 93% of the total. Novartis Pharmaceuticals Corporation paid the most, $386.